Ginkgo Bioworks Holdings (DNA) Profit After Tax Growth (3y) (2023 - 2026)

Ginkgo Bioworks Holdings (DNA) Profit After Tax Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) PAT Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 9.53%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 38.43%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 13.80%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -27.65%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 70.25%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Ginkgo Bioworks Holdings 445.24 Mn 301.37 Mn 16.38 Mn 26.02%

Historic Data

Download Data
DateValue
Mar 31, 2026 26.02%
Dec 31, 2025 49.20%
Sep 30, 2025 50.61%
Jun 30, 2025 55.83%
Mar 31, 2025 47.94%
Dec 31, 2024 31.46%
Sep 30, 2024 18.03%
Jun 30, 2024 -59.13%
Mar 31, 2024 -31.14%
Dec 31, 2023 -65.86%
Sep 30, 2023 -126.53%